Hikma Pharmaceuticals Plc
Industry Group: Pharmaceuticals
Country/Region: United Kingdom
Identifier: LON:HIK
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 158 out of 850
Universe
Global Universe 6731 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| GlaxoSmithKline Pharmaceuticals Ltd. |
23.5
Medium
|
151 out of 850 |
| Hikma Pharmaceuticals Plc |
23.7
Medium
|
158 out of 850 |
| Chemical Works of Gedeon Richter Plc |
26.6
Medium
|
282 out of 850 |
| Dong-E-E-Jiao Co., Ltd. |
36
High
|
723 out of 850 |
| Haisco Pharmaceutical Group Co., Ltd. |
36.1
High
|
732 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Top Material ESG Issues for Hikma Pharmaceuticals Plc
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Hikma Pharmaceuticals Plc's ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
